We are live on ! Find out more
TAM

TFG Asset Management Portfolio holdings

AUM $635M
1-Year Est. Return 28.07%
This Fund
S&P 500
This Quarter Est. Return
+13.2%
1 Year Est. Return
+28.07%
3 Year Est. Return
+72.07%
5 Year Est. Return
+87.41%
10 Year Est. Return
+132.97%
AUM
$635M
AUM Growth
+$120M
Cap. Flow
+$71.2M
Cap. Flow %
11.21%
Top 10 Hldgs %
74.01%
Holding
46
New
10
Increased
16
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
PATH icon
UiPath
PATH
+$61.3M
2
ALKT icon
Alkami Technology
ALKT
+$9.91M
3
CELC icon
Celcuity
CELC
+$7.4M
4
RLAY icon
Relay Therapeutics
RLAY
+$5.64M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$4.17M

Top Sells

Rank Stock Value
1
WBD icon
Warner Bros
WBD
+$18.2M
2
PRAX icon
Praxis Precision Medicines
PRAX
+$5.14M
3
AXSM icon
Axsome Therapeutics
AXSM
+$4.35M
4
SLNO
Soleno Therapeutics
SLNO
+$3.42M
5
MPLT
MapLight Therapeutics
MPLT
+$2.28M

Sector Composition

Rank Sector Weight
1 Technology 61.09%
2 Healthcare 29.27%
3 Energy 5.33%
4 Miscellaneous 3.27%
5 Communication Services 1.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
26
Nektar Therapeutics
NKTR
$2.48B
$6.07M 0.96%
86,996
-16,041
-16% -$1.17M
AMLX icon
27
Amylyx Pharmaceuticals
AMLX
$3.87B
$5.35M 0.84%
297,926
-19,951
-6% -$309K
ACAD icon
28
Acadia Pharmaceuticals
ACAD
$5.02B
$4.25M 0.67%
167,875
+23,255
+16% +$512K
RARE icon
29
CALL
Ultragenyx Pharmaceutical
RARE
$2.52B
$3.34M 0.53%
+100,000
New +$2.48M
SLN
30
CALL
Silence Therapeutics
SLN
$834M
$3.29M 0.52%
+300,000
New +$2.11M
CUE icon
31
Cue Biopharma
CUE
$203M
$2.96M 0.47%
+93,819
New +$2.12M
SNOW icon
32
Snowflake
SNOW
$114B
$2.54M 0.4%
10,000
– –
KPTI icon
33
CALL
Karyopharm Therapeutics
KPTI
$42.4M
$2.45M 0.39%
250,300
+200,300
+401% +$1.74M
ACRS icon
34
Aclaris Therapeutics
ACRS
$885M
$2.12M 0.33%
+400,000
New +$1.78M
AGIO icon
35
CALL
Agios Pharmaceuticals
AGIO
$1.99B
$1.86M 0.29%
+50,000
New +$1.52M
TECX
36
Tectonic Therapeutic
TECX
$696M
$1.6M 0.25%
46,516
+8,928
+24% +$262K
GLUE icon
37
Monte Rosa Therapeutics
GLUE
$1.14B
$1.36M 0.21%
+56,052
New +$1.06M
TENX icon
38
CALL
Tenax Therapeutics
TENX
$79.7M
$1.09M 0.17%
+75,100
New +$959K
AMLX icon
39
CALL
Amylyx Pharmaceuticals
AMLX
$3.87B
$153K 0.02%
+8,500
New +$131K
AXSM icon
40
Axsome Therapeutics
AXSM
$10.4B
– –
-20,059
Closed -$4.35M
KPTI icon
41
Karyopharm Therapeutics
KPTI
$42.4M
– –
-52,984
Closed -$460K
PRAX icon
42
Praxis Precision Medicines
PRAX
$9.63B
– –
-15,952
Closed -$5.14M
RARE icon
43
Ultragenyx Pharmaceutical
RARE
$2.52B
– –
-39,473
Closed -$980K
SLNO
44
DELISTED
Soleno Therapeutics
SLNO
– –
-102,125
Closed -$3.42M
AARD
45
Aardvark Therapeutics
AARD
$127M
– –
-316,621
Closed -$1.19M
MPLT
46
MapLight Therapeutics
MPLT
$584M
– –
-112,115
Closed -$2.28M
1
2

Similar funds

GRR
Golden Reserve Retirement Dublin, Ohio $635M AUM 25.04% 1-Year Est. Return
GAM
Gould Asset Management Claremont, California $635M AUM 14.36% 1-Year Est. Return
MPIA
Mountain Pacific Investment Advisers Boise, Idaho $635M AUM 26.7% 1-Year Est. Return
AFG
Altiora Financial Group Lebanon, Ohio $634M AUM 13.93% 1-Year Est. Return
MWA
Martel Wealth Advisors Vancouver, Washington $636M AUM 12.74% 1-Year Est. Return
MCM
Maytus Capital Management New York $636M AUM 131.32% 1-Year Est. Return
MAM
Milestone Asset Management Pittsburgh, Pennsylvania $636M AUM 22.1% 1-Year Est. Return
BAM
BOCHK Asset Management Hong Kong $634M AUM 64.99% 1-Year Est. Return

TFG Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, TFG Asset Management held 46 positions worth $635M, up 23% from $515M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

TFG Asset Management deployed $71.2M of net new capital in Q2 2026, opening 10 new positions and adding to 16 existing holdings. Its largest new stake was Alkami Technology: 600,284 shares worth $10.9M.

By sector, the portfolio is most concentrated in Technology at 61% of assets, down from 63% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was Warner Bros, an estimated $18.2M trimmed.

  • TFG Asset Management's largest Q2 2026 buy was Alkami Technology: 600,284 shares worth $10.9M.
  • TFG Asset Management added most to UiPath in Q2 2026, an estimated $61.3M increase.
  • TFG Asset Management's biggest Q2 2026 reduction was Warner Bros, cutting an estimated $18.2M.
  • TFG Asset Management fully exited Praxis Precision Medicines in Q2 2026, selling an estimated $5.14M.
  • TFG Asset Management's ten largest holdings make up 74% of its $635M portfolio in Q2 2026.
  • TFG Asset Management opened 10 new positions and closed 7 in Q2 2026.
  • TFG Asset Management's portfolio value rose 23% quarter-over-quarter to $635M.

Based on TFG Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.